Media OutReach
DHL Global Forwarding Adds to Its Asia Pacific’s Life Science and Healthcare Capabilities with Dual-Certified Cold Chain Facility in Malaysia
- First forwarder with dual-certified facility within Kuala Lumpur International Airport Free Commercial Zone for 15–25°C and 2–8°C storage, with Good Distribution Practice qualifications
- Sets new benchmark in pharmaceutical logistics with reefer truck transfers, secure cages, and eco-friendly infrastructure.
- Strengthens DHL’s network of 37 Air GxP and 12 IATA CEIV Pharma-certified stations across Asia-Pacific, reinforcing its leadership in providing compliant and sustainable healthcare logistics.
SINGAPORE – Media OutReach Newswire – 27 August 2025 – To meet the growing demand for temperature-sensitive pharmaceutical logistics, DHL Global Forwarding continues to enhance its cold chain capabilities in Malaysia, being the first forwarder to offer a cold chain facility certified for both 15–25°C and 2–8°C storage within the Kuala Lumpur International Airport (KLIA) Free Commercial Zone. Spanning over 38,000 square feet, the state-of-the-art facility is accorded both the DHL Air GxP certification and the IATA CEIV Pharma certification, delivering unmatched flexibility and regulatory compliance for Life Science and Healthcare customers.
Based on the World Health Organization’s Good Distribution and Storage Practices, the DHL Air GxP certification is a baseline requirement across all DHL pharma stations to ensure upholding of stringent quality and compliance standards. Complementing this is the IATA CEIV Pharma certification, a globally recognized standard that validates DHL’s capabilities in handling high-value, time- and temperature-sensitive pharmaceutical shipments.
“Malaysia is strategically located to serve as a regional hub for global medical technology companies, and the fast-growing market is expected to increase at a CAGR of 8.5 per cent from 2023 to 2028, reaching a market volume of US$4.5 billion by 2028,” said Praveen Gregory, Managing Director, Singapore, Malaysia and Brunei, DHL Global Forwarding. “Our cold chain infrastructure in KLIA has consistently delivered high standards in pharmaceutical logistics since its launch in 2023, and as demand across Asia Pacific accelerates, we are ready to lead with best-in-class facilities and expertise to support our customers.”
Comprehensive solutions to cater to diverse needs and maintain cold chain integrity
The facility comprises:
- Dedicated cold rooms: 1,040 square feet for 15–25°C storage and 504 square feet for 2–8°C storage, supporting up to 105 EU pallets
- Dual secure cages: Over 2,400 square feet of high-security storage with 24/7 CCTV surveillance and restricted access.
- Advanced Environment Monitoring System (EMS): 100% automated real-time storage temperature monitoring via a dual system (Testo Saveris and UniBot), with data stored for one year.
- Eco-friendly infrastructure: R448A refrigerant, food-grade epoxy flooring, airtight doors, and energy-efficient compressors.
- Operational excellence: 24/7 operations with dedicated customs brokerage and value-added services such as buyer consolidation, cross-docking, and LD3 container charging.
- Fully temperature-mapped carve-out site: Designated area that has undergone a thorough temperature mapping process, specifically designed to store or handle temperature-sensitive products
- Dehumidification system: Tailored for pharmaceutical application between the range of 55% to 70%Rh
DHL is also the only forwarder in KLIA offering reefer truck transfers from pick-up to terminal arrival and delivery. This service ensures cold chain integrity is maintained throughout the journey and minimizes third-party handling, which in turn reduces turnaround time. It also enhances cargo security and ensures compliance with Good Distribution Practice (GDP) standards.
To ensure all shipments are handled with utmost care and in compliance with the highest industry standards, all cold-chain shipments are handled by a dedicated team of Life Sciences Specialists who have completed the training and are certified. These staff undergo annual training to stay ahead of evolving industry requirements, armed with vital tools and knowledge needed to understand and meet both customer and regulatory expectations. In addition to implementing a specialized training program aligned with IATA regulatory standards across its key GxP facilities, DHL’s CIF Certified Life Sciences Specialist (CLSS) program equally provides a comprehensive curriculum of mandatory training sessions, functional courses, and material to build deep expertise in this highly specialized industry.
DHL’s commitment to green logistics is also evident in the KLIA facility’s design. The facility is built using CFC- and HCFC-free materials and is fitted with energy-saving compressors and low-noise, low-emission generators. The company is also exploring mobile freezer units capable of operating at -20°C, as well as expanding its service portfolio to include frozen commodities such as vaccines, meat, and industrial chemicals.
Asia Pacific: Fast-Growing Strategic Hub for Healthcare Logistics
Asia Pacific is rapidly emerging as a global center for pharmaceutical innovation, manufacturing, and distribution. According to an industry trend report by Data Bridge Market Research, the region’s healthcare logistics market is forecasted to grow from USD 17.6 billion in 2022 to USD 29.5 billion by 2030, at a CAGR of 7.1%. This growth is driven by aging populations, rising chronic disease prevalence, and increasing demand for biologics, vaccines, and clinical trials.
DHL is uniquely positioned to support this growth, with a robust and strategically distributed cold chain network across Asia Pacific. As part of its Strategy 2030: Accelerating Sustainable Growth, DHL Group has identified Life Sciences and Healthcare (LSH) as a key growth sector and introduced a new “DHL Health Logistics“ sector brand to drive cross-divisional growth. This reflects a broader global trend in which logistics is increasingly recognized as a critical enabler of healthcare access and patient outcomes. Earlier this year, DHL Group also announced a €500 million investment in Life Sciences infrastructure across Asia Pacific, including 300,000 square meters of fully compliant storage in 15 countries – a move that reinforces its regional logistics leadership.
Currently, DHL operates 37 Air GxP-certified stations and 12 IATA CEIV Pharma-certified stations in the region, including key hubs in Kuala Lumpur, Singapore, Tokyo, Seoul, Sydney, and Shanghai. These facilities are meticulously set up to meet the highest standards of pharmaceutical logistics, ensuring temperature integrity, regulatory compliance, and operational excellence. Each certified station is staffed by trained Life Sciences Specialists and supported by integrated supply chain capabilities, including temperature-controlled transportation, customs brokerage, real-time shipment monitoring, and post-shipment investigations.
As the healthcare industry continues to evolve, DHL remains steadfast in its mission to deliver resilient, compliant, and future-ready logistics solutions. With its expanding footprint, certified expertise, and commitment to innovation, it is well-positioned to be the logistics partner of choice for life sciences companies across Asia Pacific—ensuring that critical healthcare products reach patients safely, efficiently, and sustainably.
Hashtag: #DHL
The issuer is solely responsible for the content of this announcement.
DHL – The logistics company for the world
DHL is the leading global brand in the logistics industry. Our DHL divisions offer an unrivalled portfolio of logistics services ranging from national and international parcel delivery, e-commerce shipping and fulfillment solutions, international express, road, air and ocean transport to industrial supply chain management. With approximately 400,000 employees in more than 220 countries and territories worldwide, DHL connects people and businesses securely and reliably, enabling global sustainable trade flows. With specialized solutions for growth markets and industries including technology, life sciences and healthcare, engineering, manufacturing & energy, auto-mobility and retail, DHL is decisively positioned as “The logistics company for the world”.
DHL is part of DHL Group. The Group generated revenues of approximately 84.2 billion euros in 2024. With sustainable business practices and a commitment to society and the environment, the Group makes a positive contribution to the world. DHL Group aims to achieve net-zero emissions logistics by 2050.
As awareness around women’s health continues to grow, menopause remains a life stage that is frequently underserved by mainstream health solutions. JR Life Sciences is responding to this gap with a science-backed, plant-derived formulation that offers a natural alternative to conventional hormone-based therapies, one that is both accessible and aligned with the preferences of today’s health-conscious consumer.
Menopause Relief is a once-daily capsule containing three plant-based phytoestrogens, each selected for their clinically studied benefits in managing menopause symptoms and supporting long-term health. The formulation is free from synthetic hormones and is suitable for both vegetarian and vegan diets, making it broadly accessible across diverse consumer lifestyles.
Key active ingredients include:
- Lifenol Hops Extract (8-PN phytoestrogen): Shown to lessen hot flushes, night sweats, sleep disturbances, restlessness and irritability while helping to maintain total-body bone-mineral density.
- Flax Lignan (SDG phytoestrogen): Provides gentle hormonal support that helps balance oestrogen levels during the transition.
- Soy Isoflavone (genistein and daidzein): Supports bone strength, reduces hot flashes and steadies mild mood swings.
The launch of Menopause Relief reflects a broader strategic priority for JR Life Sciences: to expand its women’s health portfolio in response to growing consumer demand for natural health solutions. In Singapore, where an ageing population is driving increased interest in preventive health and targeted supplementation, the company sees a significant opportunity to better serve women navigating the menopause transition.
Holistic Way currently distributes a comprehensive range of nutraceuticals across key health categories, including:
- Musculoskeletal Health: Products categorised under joint supplements to address knee pain and mobility concerns in ageing demographics.
- Immunity & General Health: Daily essentials ranging from Vitamin C tablets and multivitamin supplements to vitamins for the immune system.
- Specialised Care: Targeted formulations including eye health supplements, probiotics supplements, and heart health supplements.
- Beauty & Wellness: Functional supplements such as collagen shots, hair growth supplements, and anti-ageing supplements.
As JR Life Sciences prepares for 2027, its focus remains on addressing unmet market needs and evolving consumer expectations. Guided by a commitment to science-backed innovation and quality, the company continues to invest in building a future-ready product pipeline that supports long-term well-being and reinforces trust among consumers in Singapore and beyond.
Menopause Relief is now available through Holistic Way’s retail and digital channels. For more information, visit https://holisticway.com.sg/.
Hashtag: #HolisticWay
The issuer is solely responsible for the content of this announcement.
About Holistic Way
Holistic Way is a leading Singapore-based health supplement brand under JR Life Sciences, committed to supporting holistic wellbeing through science-led nutrition. The brand offers a comprehensive range of supplements formulated to support key health areas, including immunity, hormonal balance, joint health, digestive wellness, and healthy ageing. Guided by evidence-based research and stringent quality standards, Holistic Way focuses on delivering effective, reliable solutions that address both everyday wellness needs and specific life-stage concerns. Through its emphasis on scientific integrity and product excellence, Holistic Way empowers individuals to take proactive control of their health and well-being.
Emerging economies are becoming the EV industry’s fastest-growing markets, creating new opportunities for automakers with an international footprint. VinFast’s latest expansion reflects that shift.
DUBAI, UNITED ARAB EMIRATES – Media OutReach Newswire – 5 August 2026 – For much of the past decade, the global electric vehicle conversation has revolved around three markets: China, the United States, and Europe. But recent industry data suggests the next chapter may be written elsewhere.
According to the International Energy Agency (IEA), global car sales fell about 5% in the first half of 2026 as economic pressures, fuel price volatility and policy changes weighed on demand in China and the US. Yet electric vehicle sales rebounded strongly in the second quarter, reaching record levels in 50 countries. Markets including Vietnam, India, Australia and South Korea roughly doubled EV sales compared with a year earlier, while more than 90 countries posted year-on-year growth during the first half of the year.
The shift reflects a broader change in where future industry growth is likely to come from. While China remains the world’s largest EV market, the IEA expects sales there to stagnate this year for the first time this decade, even as electric vehicles account for more than 60% of new car sales. Meanwhile, emerging markets are becoming increasingly important, supported by expanding policy incentives, growing charging infrastructure and rising consumer interest.
The agency also notes that China and other emerging economies are expected to account for around 60% of global car demand over the next decade, making success in these markets an increasingly important determinant of future automotive leadership.
VinFast’s latest performance reflects this changing landscape.
The Vietnamese automaker delivered 70,085 electric vehicles globally in the second quarter of 2026, up 96% year-on-year, bringing first-half deliveries to 128,662 vehicles, a 78% increase from the same period last year. The company’s two-wheel business also continued to expand rapidly, with 286,039 electric scooters and e-bikes delivered during the quarter, up 311% year-on-year.
The delivery mix also highlights the importance of products designed for diverse market needs. Models ranging from the compact VF 3 and VF 5 to the Limo Green MPV and the newly introduced VF MPV 7 all contributed meaningfully to second-quarter volumes, suggesting demand is spread across both personal mobility and commercial transportation segments.
Just as significant is where those vehicles are going.
In July, VinFast exported more than 5,000 electric vehicles aboard two dedicated vessels. One shipment, consisting of approximately 1,500 VF 6 SUVs, was designated for partner Green SM’s planned expansion in Europe, while another transported more than 3,500 vehicles to the Philippines and Indonesia. The voyages marked VinFast’s 37th and 38th international export shipments in fewer than four years, underscoring the increasing operational scale behind its global expansion.
VinFast’s effort in international market, including in the Middle East, shows that as growth becomes more geographically diversified, automakers can no longer rely on a handful of mature markets to drive expansion. Instead, success will increasingly depend on building products, distribution networks and operations that can compete across a wide range of emerging economies.
For the global EV industry, the center of gravity is not disappearing from established markets. It is becoming far more distributed. VinFast’s recent momentum suggests that companies positioned across multiple high-growth regions may be among the best placed to benefit from that shift.
Hashtag: #VinFast
The issuer is solely responsible for the content of this announcement.
Media OutReach
EM Services and SPTel Partner to Advance Smart Estate Management Through Digital Connectivity and IoT Solutions
- Faster detection of estate issues
- Faster response and resolution times
- Better use of manpower and resources
- Better services and living environments for residents
CEO
EM Services
Chief Executive Officer
SPTel
Hashtag: #EMServices #SPTel
The issuer is solely responsible for the content of this announcement.
About EM Services
About SPTel
